Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...
In their normal state, genes that code for the normal proteins controlling these critical processes are called proto-oncogenes. However, once they are altered (see below) to become oncogenes ...
Hosted on MSN9mon
Pipeline Moves: Investigator-led trial of Lilly’s merestinib in solid tumours terminatedHER2-negative breast cancer candidates' chances ... Merestinib is an inhibitor of the proto-oncogene c-Met, also known as hepatocyte growth factor receptor [HGFR]. The drug binds to c-Met, to ...
"From the excitement of identifying HER2 gene amplification and resultant protein overexpression as a targetable oncogene, through the development of drugs targeting HER2 amplification and ...
"From the excitement of identifying HER2 gene amplification and resultant protein overexpression as a targetable oncogene, through the development of drugs targeting HER2 amplification and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback